Company Overview and News


Add BIIB
to your dashboard

Headline News

Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?

2017-11-23 seekingalpha
Shares have risen by 75% since bringing this stock to the attention of readers three weeks ago. (388-3)

Your Daily Pharma Scoop: Exelixis Still Attractive, Portola's BevyxXa, Pluristem Patent

2017-11-23 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (251-1)

Should You Buy the Beaten Down Blue-Chip Stocks?

2017-11-22 zacks
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service, shares some of her top value investing tips and stock picks. (106-0)

Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

2017-11-22 zacks
Pipeline and regulatory updates were the focus this week with Ultragenyx Pharmaceutical (RARE - Free Report) gaining FDA approval for its first drug while companies like Cytokinetics (CYTK - Free Report) and Acorda Therapeutics (ACOR - Free Report) were hit by pipeline setbacks. Recap of the Week’s Most Important Stories Ultragenyx Gets FDA Approval for Rare Genetic Disease Drug: Ultragenyx gained FDA approval for its first drug, Mepsevii (vestronidase alfa), for the treatment of children and adults with mucopolysaccharidosis VII (MPS 7), also known as Sly syndrome. (201-0)

BIIB Stock: Bet on Biogen Inc for Easy Profits Into the New Year | InvestorPlace

2017-11-21 investorplace
Biotech stocks have been a political football for over a year. The negative political rhetoric started during the 2016 U.S. elections. Candidate Hillary Clinton and now President Donald Trump both have persecuted the sector for unfair pricing practices. (55-1)

Understanding Aducanumab's Potential In Alzheimer's

2017-11-21 seekingalpha
Additional data from a Phase 1 trial on Aducanumab has been reported this summer, while the drug is in Phase 3 testing. (349-1)

Sales Growth Hamper Biogen (BIIB) Rating

2017-11-21 investorplace
Biogen Inc (NASDAQ:BIIB) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 781 company GICS Health Care sector. BIIB's market value is $66.4 billion which places it in the top decile in its industry group. Portfolio Grader's current ranking for BIIB puts it 142 among the 349 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 349 among the 781 companies in the sector, and number 2,252 in the nearly 5,000 company Portfolio Grader universe. (50-1)

Tracking Jeffrey Ubben's ValueAct Portfolio - Q3 2017 Update

2017-11-20 seekingalpha
The top three positions are Twenty First Century Fox, Alliance Data Systems, and Baker Hughes and they add up to ~38% of the portfolio. (288-1)

Steven Cohen’s 6 Best Performing Stocks That Still Have Big Upside

2017-11-17 investorplace
If you haven’t heard of Billionaire Steven Cohen, you may already know a little about him if you’ve watched Showtime’s hit series “Billions.” Damian Lewis plays the show’s main character Bobby Axelrod that very loosely portrays Cohen and his former hedge fund SAC Capital. (132-3)

Another Threat For Biogen's MS Franchise

2017-11-15 seekingalpha
Much has been said and written about the looming threat to Biogen's (BIIB) multiple sclerosis (MS) franchise from pricing pressure, competition in general and generic competition specifically for oral therapies. Biogen and other companies in the MS space have been under pressure from lawmakers over the pricing of MS drugs. Biogen's Zinbryta (AbbVie (ABBV) is a co-promoter for the drug) in particular has faced the wrath of lawmakers in recent months. (64-0)

Tracking Seth Klarman's Baupost Group Holdings - Q3 2017 Update

2017-11-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (514-8)

Biogen (BIIB) a Hold on Feeble Quant Score

2017-11-13 investorplace
Biogen Inc (NASDAQ:BIIB) is classified as a constituent of the 349 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. BIIB's market value is $65.7 billion which falls in the top 10% of its industry group. The ranking for BIIB by Portfolio Grader places it 145 among the 349 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 351 among the 782 companies in the sector, and number 2,233 in the nearly 5,000 company Portfolio Grader universe. (50-0)

Biotech ETFs: What Lies Ahead?

2017-11-13 zacks
So far, it’s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date. This is in sharp contrast to last year’s performance when the Index was down 19.1% with several factors including the drug pricing controversy weighing on the sector. (177-0)

Regeneron Falls On Q3 Report: Weighing The Pros And Cons

2017-11-13 seekingalpha
REGN had a seemingly strong quarter, but on reflection, the Street was not impressed, and it continued in its bear market following its June peak above $540. (106-0)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

CUSIP: 09062X903